SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Clinical Development

Calls to increase EU chemical competitiveness

02-Dec-2005 - A Strategic Research Agenda (SRA) was launched last week in a move to bolster the chemistry and biotechnology industry's contribution to European growth and competitiveness.

Collaboration to drive down drug prices

02-Dec-2005 - Escalating drug costs could be driven down by up to $20 billion a year and dwindling drug pipelines improved if a newly-formed US research group is successful.

Direct Capital acquires 51pc of NZ Pharmaceuticals

28-Nov-2005 - Private equity firm, Direct Capital has acquired a shareholding of 51 per cent in New Zealand Pharmaceuticals (NZP). The investment by Direct Capital aims to tap into the growing potential...

Patheon dominates contract manufacturing

23-Nov-2005 - Patheon has received the 2005 Contract Manufacturing Company of the Year Award from consultancy firm Frost & Sullivan, in recognition of its customer service and innovative market growth strategies.

In-Pharma focus: Clariant's chemistry.

18-Nov-2005 - The Pharmaceutical Fine Chemicals Business of Clariant took the opportunity to review new developments at the CPhI Expo in Madrid, Spain, making announcements on new investments in facilities in Europe...

Pliva posts 9-month net loss of $34 million

14-Nov-2005 - Pliva released its financial results for the first nine months of 2005, which revealed a net loss of $34 million, as the drug maker tries to recover from its loss-making...

Dr. Reddy's expands into Mexico

11-Nov-2005 - Dr. Reddy's Laboratories (DRL) has signed a definitive agreement to acquire Roche's Mexican API business, in a move to drive the next wave of growth in its custom pharmaceutical services...

New webcam gives Cook competitive edge

11-Nov-2005 - Cook Pharmica will be the first contract manufacturer to offer live webcam services, an innovation that will enable both customers and regulatory agencies to view production as it occurs.

Lanxess sets up new custom manufacturing company

09-Nov-2005 - Lanxess has said it will spin-off its Fine Chemicals operations into a separate business unit that is expected to become independent as of the second quarter next year.

New study may rock generics drug market

09-Nov-2005 - New findings may have significant implications for the growing generics drugs industry, by challenging previous assumptions that all formulations of the same active pharmaceutical ingredient (API) are therapeutically equivalent.

Fisher Scientific posts increase in 3Q profit

09-Nov-2005 - Fisher Scientific International reported it's third quarter performance for 2005, which revealed profit had more than doubled as a result of improved sales and fewer acquisition related charges.

pSivida breaks into Chinese drug market

04-Nov-2005 - pSivida has signed a licensing agreement with Beijing's Med-Pharm, in a move that will facilitate distribution of BrachySil in China - the world's fastest growing market for pharmaceuticals.

AssurX launches corporate compliance system

04-Nov-2005 - AssurX have launched a software process for document control, which will enable pharmaceutical manufacturing companies to streamline their approach to monitoring safety issues and overall quality control efforts.

Lonza/Solvias partnership flourishes

02-Nov-2005 - Lonza and Solvias have confirmed their long-term collaboration in the development and transfer of asymmetric reactions to an industrial scale.

Flamel's finances flounder after string of setbacks

02-Nov-2005 - Troubled firm Flamel reported a sharp decrease in total third quarter revenues - $3.1 million (€2.6 million), compared to $13.3 million this time last year - resulting in a net loss $11.9 million.

Utah Medical victory in FDA legal dispute

31-Oct-2005 - A federal US judge set a precedent last week in ruling against the US Food & Drug Administration (FDA) in a four-year dispute against Utah Medical Products.

Contract manufacturing boom benefits Penn Pharmaceuticals

28-Oct-2005 - Penn Pharmaceutical Services has reported strong sales figures for the fifth consecutive year, with a key driver of recent growth being attributed to a boom in contract manufacturing as well...

Biopharma sector hits Cambrex 3Q hard

28-Oct-2005 - Cambrex has recorded a gain in the third quarter of this year, with growth in its Bioproducts and Human Health segments. The company's troublesome BioPharma division continues to underperform, indicative...

Cardinal Health quarterly profit rises

28-Oct-2005 - Cardinal Health reported a varied first quarter, with sales and income receiving substantial gains due to across-the-board improvement in pharmaceutical distribution, medical products and services and clinical technologies.

Companies collaborate in generic injectable deal

26-Oct-2005 - Par Pharmaceuticals has announced a collaboration with MN Pharmaceuticals to develop and market generic versions of injectable pharmaceuticals in which Par enters a new market segment.

Millipore reports lower third-quarter profit

26-Oct-2005 - Millipore, a maker of purification systems used in drug manufacturing, reported lower third-quarter profit due to acquisition-related tax charges and manufacturing consolidation costs.

Equity firm purchases Reilly and Velsicol

26-Oct-2005 - Arsenal Capital Partners has acquired a majority stake in Reilly Industries for €209 million and Velsicol Chemical for an undisclosed fee. The purchases continue a rich vein of activity for...

West Pharma's gloomy outlook overshadows 3Q profit

21-Oct-2005 - Drug packaging maker West Pharmaceutical Services release its 3Q results, which indicate a rise in profits but fell short of analyst estimates, due to slow sales in some segments and...

Bruker AXS to acquire Roentec

19-Oct-2005 - Bruker AXS, a subsidiary of the Bruker BioSciences Corporation, has announced an agreement to purchase Roentec, an x-ray microanalysis instrumentation company that signals Bruker's intention to reinforce its standing within...

Alpharma acquisition boosts global position for Actavis

19-Oct-2005 - Actavis's $810 million (€677 million) cash acquisition of Alpharma's US and international generic drugs division is part of the firm's strategy to become one of the global leaders in the sector.

Key Industry Events

 

Access all events listing

Our events, Shows & Conferences...